# Merck KGaA, Darmstadt, Germany clinical trials: 275 (2026)

ClinicalTrials.gov lists 275 trials with Merck KGaA, Darmstadt, Germany as lead sponsor, 0 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Merck KGaA, Darmstadt, Germany: 275 rows for $13.75, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/merck-kgaa-darmstadt-germany

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 275
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 275, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 28, 2019 | NCT03858049 | Efficacy and Safety of Crinone Versus Combination Medication (ACCESS) | Merck KGaA, Darmstadt, Germany | Phase 4 | Terminated | Infertility | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03858049) |
| February 19, 2019 | NCT03845140 | L-PZQ ODT in Schistosoma Infected Children | Merck KGaA, Darmstadt, Germany | Phase 3 | Completed | Schistosomiasis | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03845140) |
| November 19, 2018 | NCT03745144 | Effects of Cladribine Tablets on the PK of Microgynon® | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Relapsing Multiple Sclerosis (RMS) | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03745144) |
| October 30, 2018 | NCT03725072 | Human Absorption, Distribution, Metabolism and Excretion (ADME) of \[14C\]-Evobrutinib | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03725072) |
| October 24, 2018 | NCT03717155 | Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC | Merck KGaA, Darmstadt, Germany | Phase 2 | Completed | Squamous Non-Small Cell Lung Cancer | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03717155) |
| September 18, 2018 | NCT03676322 | Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03676322) |
| August 14, 2018 | NCT03629223 | Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03629223) |
| August 14, 2018 | NCT03628339 | Effect of Tepotinib on PK of CYP3A Substrate Midazolam | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03628339) |
| July 12, 2018 | NCT03584321 | Retrospective Study to Estimate the Current Status of Patients With Non-Obstructive coroNary Artery Disease | Merck KGaA, Darmstadt, Germany | Observational | Completed | Non-Obstructive Coronary Artery Disease | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03584321) |
| July 11, 2018 | NCT03583385 | Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03583385) |
| July 11, 2018 | NCT03583346 | Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in... | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Osteoarthritis, Knee | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03583346) |
| June 25, 2018 | NCT03566810 | Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt) | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03566810) |
| May 22, 2018 | NCT03531762 | Effect of a Proton Pump Inhibitor on the PK of Tepotinib | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03531762) |
| May 14, 2018 | NCT03523390 | Phase I/Ib Multiple Ascending Dose Study in China | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Metastatic Solid Tumors | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03523390) |
| April 10, 2018 | NCT03492437 | Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03492437) |
| March 16, 2018 | NCT03467971 | A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03467971) |
| March 16, 2018 | NCT03467945 | Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03467945) |
| February 19, 2018 | NCT03437447 | Praziquantel Bioequivalence Study | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03437447) |
| February 19, 2018 | NCT03436394 | Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK) | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Renal Impairment | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03436394) |
| January 8, 2018 | NCT03393208 | Glucophage Immediate Release (GIR) China Bioequivalence Study | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Healthy | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03393208) |
| December 29, 2017 | NCT03387059 | Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle | Merck KGaA, Darmstadt, Germany | Phase 4 | Terminated | Infertility | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03387059) |
| December 29, 2017 | NCT03387046 | A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS) | Merck KGaA, Darmstadt, Germany | Phase 2 | Terminated | Multiple Sclerosis, Relapsing-Remitting | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03387046) |
| December 12, 2017 | NCT03369665 | Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS) | Merck KGaA, Darmstadt, Germany | Phase 4 | Completed | Multiple Sclerosis | 485 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03369665) |
| December 6, 2017 | NCT03364036 | Evaluation of the Onset of Action in Highly Active MS (MAGNIFY) | Merck KGaA, Darmstadt, Germany | Phase 4 | Completed | Multiple Sclerosis | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03364036) |
| October 13, 2017 | NCT03309150 | ATRi Transition Rollover Study | Merck KGaA, Darmstadt, Germany | Phase 1 | Completed | Advanced Stage Solid Tumors | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03309150) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 52 |
| Phase 1/2 | 9 |
| Phase 2 | 33 |
| Phase 3 | 42 |
| Phase 4 | 46 |
| Not applicable | 2 |
| Observational | 91 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 234 |
| Terminated | 36 |
| Withdrawn | 4 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Sclerosis | 36 |
| Infertility | 35 |
| Multiple Sclerosis, Relapsing-Remitting | 26 |
| Growth Disorders | 20 |
| Helping Behavior | 15 |
| Carcinoma, Non-Small-Cell Lung | 14 |
| Colorectal Neoplasms | 12 |
| Neoplasm Metastasis | 10 |
| Hypertension | 9 |
| Dwarfism, Pituitary | 9 |
| Diabetes Mellitus | 7 |
| Neoplasms | 7 |
| Polycystic Ovary Syndrome | 6 |
| Squamous Cell Carcinoma of Head and Neck | 6 |
| Diabetes Mellitus, Type 2 | 5 |
| Lung Neoplasms | 4 |
| Neoplasms, Squamous Cell | 4 |
| Psoriasis | 4 |
| Turner Syndrome | 4 |
| Stomach Neoplasms | 4 |
| Osteoarthritis, Knee | 3 |
| Carcinoma | 3 |
| Head and Neck Neoplasms | 3 |
| Ovarian Hyperstimulation Syndrome | 3 |
| Recurrence | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Day care centers in the United States](https://specstream.ai/data/businesses/day-care-centers/united-states)
- [Food and beverage consultants in the United States](https://specstream.ai/data/businesses/food-and-beverage-consultants/united-states)
- [Iron fabricators in the United States](https://specstream.ai/data/businesses/iron-fabricators/united-states)
- [Office cleaning companies in the United States](https://specstream.ai/data/businesses/office-cleaning-companies/united-states)
- [Real estate investment firms in the United States](https://specstream.ai/data/businesses/real-estate-investment-firms/united-states)
- [Tiling contractors in the United States](https://specstream.ai/data/businesses/tiling-contractors/united-states)
